Shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL – Get Free Report) have earned an average rating of “Moderate Buy” from the four research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $10.00.
Several equities analysts recently commented on CRDL shares. Wall Street Zen lowered Cardiol Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Canaccord Genuity Group lifted their price target on Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiol Therapeutics in a research report on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Wednesday, September 23rd. Finally, B. Riley Financial started coverage on Cardiol Therapeutics in a report on Wednesday, August 26th. They issued a “buy” rating and a $11.00 price objective on the stock.
Read Our Latest Research Report on Cardiol Therapeutics
Institutional Trading of Cardiol Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Concurrent Investment Advisors LLC purchased a new position in Cardiol Therapeutics during the 2nd quarter worth $27,000. Royal Bank of Canada increased its stake in Cardiol Therapeutics by 62.3% in the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after purchasing an additional 8,306 shares during the period. Parallel Advisors LLC acquired a new position in Cardiol Therapeutics in the third quarter valued at $32,000. Cibc World Market Inc. purchased a new stake in shares of Cardiol Therapeutics in the third quarter valued at about $55,000. Finally, PVG Asset Management Corp raised its holdings in shares of Cardiol Therapeutics by 10.3% in the first quarter. PVG Asset Management Corp now owns 107,165 shares of the company’s stock valued at $145,000 after buying an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 12.49% of the company’s stock.
Cardiol Therapeutics Stock Performance
NASDAQ CRDL opened at $1.00 on Monday. The stock has a market cap of $121.62 million, a PE ratio of -4.17 and a beta of 1.03. Cardiol Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.34. The stock has a fifty day simple moving average of $1.42 and a 200-day simple moving average of $1.30.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Research analysts predict that Cardiol Therapeutics will post -0.19 EPS for the current year.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.
Featured Articles
- Five stocks we like better than Cardiol Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
